An interventional study of AI-Enabled Stratified Management System and Usual Post-Discharge Care in Premature Coronary Heart Disease, sponsored by China National Center for Cardiovascular Diseases. Recruiting at 16 sites in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Prevention
Among 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases — 12 open to participants now, 13 under way, none of them phase 3. Coronary Disease · China National Center for Cardiovascular Diseases.
Among the 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases, this one has the largest planned enrollment of the 13 interventional ones that give a count, is one of 6 that started in 2025, is one of 7 with no phase, reaches primary completion later than 10 of the 12 other live ones, and was the 18th registered.
1,520 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →12 of the 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases are open now, in 1 country. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
China National Center for Cardiovascular Diseases · Sites in China
China National Center for Cardiovascular Diseases · Sites in China
China National Center for Cardiovascular Diseases · Sites in China
China National Center for Cardiovascular Diseases · Sites in China
By country, each count listing its studies:
Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 6 started in 2025.
This study's planned enrollment of 4,900 is above the median of 160 across 778 interventional studies indexed under Coronary Disease.
Median enrollment 240 across the 13 interventional studies, 5,000 across the 12 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
China National Center for Cardiovascular Diseases is the lead sponsor of 269 studies on the registry; 141 are open to participants now.
4 of the studies in Coronary Disease by China National Center for Cardiovascular Diseases that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07259278China National Center for Cardiovascular DiseasesIntelligent Management Platform for Guiding Exercise Rehabilitation in Coronary Heart Disease Patients | 2026-11-30 |
| NCT07230847China National Center for Cardiovascular DiseasesA Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug-coated Stents and the Xience Drug-eluting Stent System in Patients With Acute Coronary Syndrome and High Bleeding Risk Using Optical Coherence Tomography | 2026-12-31 |
| NCT07766551China National Center for Cardiovascular DiseasesConstruction and Validation of a Coronary Artery Disease-Specific Large Language Model and Its Evaluation Framework (CorAI) | 2027-01-01 |
| NCT07004452China National Center for Cardiovascular DiseasesMulti-modal Adverse Events Prediction for Premature Coronary Heart Disease Trial: MAP-CHD Trial | 2027-07 |
Among the 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if an AI-enabled stratified management system (SMART-CHD) can improve post-discharge outcomes in adults aged 18-45 with premature coronary artery disease. The main questions it aims to answer are:
Researchers will compare SMART-CHD to standard discharge management (verbal and printed instructions on medications, follow-up timelines and lifestyle advice) to see if the AI-driven platform leads to fewer adverse events and improved risk-factor profiles.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the intervention group will use SMART-CHD alongside usual post-discharge care.
Combination Product: AI-Enabled Stratified Management System · Combination Product: Usual Post-Discharge Care
Participants in the control group will receive usual discharge protocol comprising verbal and printed discharge instructions addressing medication schedules, follow-up timelines, and lifestyle optimization strategies.
Combination Product: Usual Post-Discharge Care
After discharge, participants install SMART-CHD, sync their EHR data, and complete a 10-minute orientation. They then use the app's OCR-assisted surveys to report lifestyle, lab, and event data, while paired wearables stream continuous vitals. AI voice calls and a CRC-managed WeChat group deliver reminders and support. The app's embedded predictive models stratify them into risk tiers and generate tier-specific follow-up schedules. Personalized lifestyle modification guidance, dietary plans, and medication adjustment recommendations are generated by the platform's module. Automated alerts and teleconsultation options are triggered upon detection of high-risk signs or abnormal results, ensuring timely clinical intervention and enhanced secondary prevention.
Usual discharge protocol comprising verbal and printed discharge instructions addressing medication schedules, follow-up timelines, and lifestyle optimization strategies.
Cardiovascular Composite Endpoint Events
A composite of all-cause death, myocardial infarction, stroke, and unplanned cardiovascular-related rehospitalization.
Time frame: Assessed at 12 months post-discharge
Individual components of cardiac events
All-cause death, myocardial infarction, stroke, and unplanned cardiovascular-related rehospitalization
Time frame: Assessed at 12 months post-discharge
LDL-C level
Low-density lipoprotein cholesterol level. Unit of Measure: mmol/L.
Time frame: Assessed at 12 months post-discharge
LDL-C Goal Attainment
Achieving LDL-C \< 1.8 mmol/L.
Time frame: Assessed at 12 months post-discharge
Blood pressure level
Systolic blood pressure and Diastolic blood pressure. Unit of Measure: mmHg.
Time frame: Assessed at 12 months post-discharge
Blood pressure goal attainment
Achieving target BP \<130/80 mmHg.
Time frame: Assessed at 12 months post-discharge
Hemoglobin A1c level
Glycated hemoglobin (HbA1c). Unit of Measure: Percentage (%).
Time frame: Assessed at 12 months post-discharge
Smoking
Self-reported current smoking status. Unit of Measure: Number and percentage of current smokers
Time frame: Assessed at 12 months post-discharge
Medication adherence to antiplatelet agents and statins
Adherence is defined as self-reported use of the medication for more than 80% of the time during the past month
Time frame: Assessed at 12 months post-discharge
Plan to share: Yes — Individual participant data (IPD) that underlie the results reported in publications will be shared, including all collected de-identified IPD.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Data will be available beginning 6 months after publication of the primary results and will remain available for at least 5 years thereafter.
Access criteria: De-identified IPD and supporting documents will be made available upon reasonable request to the Principal Investigator (PI). Requests must include a methodologically sound proposal and intended use. Access will be granted at the discretion of the PI after review of the request.
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Aug 2028, 36 months after the start.
Of 178 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 36 months is above that.
Counting every sponsor, half of 200 studies reached it within 25 months; a quarter within 14 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China National Center for Cardiovascular Diseases →